Search for: "Mills v. Pfizer, Inc"
Results 1 - 20
of 20
Sorted by Relevance
|
Sort by Date
14 Jul 2010, 10:49 am
Traders, Inc. v. [read post]
19 Feb 2016, 11:57 am
Gold Issue Mining & Milling Co., 243 U.S. 93 (1917), to support general jurisdiction by consent. [read post]
10 Jun 2010, 3:58 am
Actavis Inc. et al. [read post]
18 Jul 2014, 11:55 am
Pfizer, Inc., 716 F.3d 1087, 1092-93 (8th Cir. 2013). [read post]
2 Dec 2011, 2:00 pm
Mills v. [read post]
10 Sep 2019, 8:03 pm
More recently, in Pfizer, Inc. v Arch Ins. [read post]
13 Jul 2010, 11:07 am
Pfizer, Inc. [read post]
21 Jun 2013, 12:30 pm
’” Pfizer Inc. v. [read post]
24 Sep 2009, 5:09 am
Plough, Inc., 863 P.2d 167, 177-78 (Cal. 1993); Patton v. [read post]
28 Sep 2009, 1:31 am
Plough, Inc., 863 P.2d 167, 177-78 (Cal. 1993); Patton v. [read post]
28 Sep 2009, 1:31 am
Plough, Inc., 863 P.2d 167, 177-78 (Cal. 1993); Patton v. [read post]
28 Sep 2009, 1:31 am
Plough, Inc., 863 P.2d 167, 177-78 (Cal. 1993); Patton v. [read post]
6 Mar 2014, 12:41 pm
Pfizer, Inc., 490 F. [read post]
6 Feb 2009, 8:19 am
Spisak Issue: Did the Sixth Circuit contravene AEDPA by improperly extending Mills v. [read post]
29 Dec 2008, 9:00 pm
Pfizer Inc., 867 N.Y.S.2d 425 (N.Y.A.D. 2008) (state appellate holding that plaintiff's home state controls on choice of law; similar to, but much better than, Desiano); (15) Vanderwerf v. [read post]
27 Jul 2012, 12:40 pm
Pfizer, Inc., 990 A.2d 17, 21 n.1 (Pa.Super. 2010) (rejecting fraud claim concerning promotion “for off-label uses for which the effectiveness had not been scientifically demonstrated”). [read post]
15 Jul 2010, 2:39 pm
Wyeth, Inc., 613 F. [read post]
5 May 2009, 5:57 am
The cases, both on alleged failure to warn of the risk of suicide, include one against Glaxo over Paxil and one against New York-based Pfizer Inc. over Zoloft. [read post]
4 Nov 2021, 5:37 am
And if the case is seen as run-of-the-mill within its category, then allowing pseudonymity would imply that other cases in the category should be pseudonymized as well. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
